Larimar Therapeutics, Inc. (NASDAQ:LRMR) Holdings Boosted by SG Americas Securities LLC

SG Americas Securities LLC grew its holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) by 35.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,391 shares of the company’s stock after purchasing an additional 5,042 shares during the period. SG Americas Securities LLC’s holdings in Larimar Therapeutics were worth $75,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Janus Henderson Group PLC lifted its position in shares of Larimar Therapeutics by 27.2% in the third quarter. Janus Henderson Group PLC now owns 5,566,855 shares of the company’s stock worth $36,379,000 after purchasing an additional 1,189,467 shares in the last quarter. Sphera Funds Management LTD. increased its stake in Larimar Therapeutics by 32.6% in the 3rd quarter. Sphera Funds Management LTD. now owns 414,478 shares of the company’s stock valued at $2,715,000 after buying an additional 102,009 shares during the period. Jane Street Group LLC lifted its position in Larimar Therapeutics by 80.1% in the 3rd quarter. Jane Street Group LLC now owns 113,783 shares of the company’s stock worth $745,000 after buying an additional 50,622 shares in the last quarter. GSA Capital Partners LLP raised its holdings in shares of Larimar Therapeutics by 108.9% during the third quarter. GSA Capital Partners LLP now owns 107,408 shares of the company’s stock worth $704,000 after acquiring an additional 55,984 shares in the last quarter. Finally, Wellington Management Group LLP increased its position in Larimar Therapeutics by 152.5% in the 3rd quarter. Wellington Management Group LLP now owns 105,246 shares of the company’s stock worth $689,000 after purchasing an additional 63,563 shares during the last quarter. 91.92% of the stock is currently owned by institutional investors and hedge funds.

Larimar Therapeutics Trading Up 1.2 %

Shares of LRMR stock opened at $3.27 on Friday. The firm’s fifty day simple moving average is $4.10 and its 200 day simple moving average is $6.24. The firm has a market capitalization of $208.66 million, a P/E ratio of -2.84 and a beta of 0.91. Larimar Therapeutics, Inc. has a 1 year low of $3.01 and a 1 year high of $13.68.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on LRMR. Truist Financial assumed coverage on Larimar Therapeutics in a report on Wednesday, January 29th. They set a “buy” rating and a $18.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Larimar Therapeutics in a research report on Friday, January 24th. Finally, William Blair reissued an “outperform” rating on shares of Larimar Therapeutics in a research report on Tuesday, November 19th. Eleven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Larimar Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $20.13.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.